American Healthcare REIT, Inc. (AHR) Q2 2025 Earnings Call Transcript

American Healthcare REIT (AHR) reported a robust Q2 2025, significantly raising its full-year 2025 Normalized FFO per share guidance to $1.64-$1.68 and total portfolio same-store NOI growth to 11%-14%. This strong performance was driven by exceptional organic growth, with Trilogy and SHOP segments achieving 18.3% and 23% same-store NOI growth respectively, fueled by rising occupancies and RevPOR, notably from optimizing higher-paying Medicare Advantage contracts. AHR also continued its accretive acquisition strategy, closing $255 million in deals year-to-date and maintaining a $300 million pipeline, while improving its net debt to EBITDA to 3.7x through strong earnings and ATM equity raises. This strategic positioning allows AHR to capitalize on favorable long-term demographic trends and the supply-demand imbalance in the seniors housing sector.

Analysis

American Healthcare REIT (AHR) reported a strong second quarter for 2025, underscored by a significant increase in its full-year guidance. The company raised its Normalized FFO per share forecast to a range of $1.64 to $1.68, driven by robust operational performance, particularly within its operating portfolio. Total portfolio same-store NOI grew 13.9% year-over-year, with the Integrated Senior Health Campuses (Trilogy) and SHOP segments delivering exceptional growth of 18.3% and 23.0%, respectively. This outperformance is attributable to a combination of rising occupancy and strong rate growth; Trilogy's occupancy increased 219 basis points to 88.9% while average daily rates rose 7.8%, fueled by a strategic shift toward higher-paying Medicare Advantage contracts, which now account for 7.2% of resident days versus 5.8% a year ago. Concurrently, AHR executed on its growth strategy by closing approximately $255 million in acquisitions year-to-date and maintaining a pipeline of over $300 million in awarded deals not yet factored into guidance. The company's balance sheet has also strengthened considerably, with net debt to EBITDA decreasing to 3.7x from 4.5x in the prior quarter, facilitated by strong earnings and disciplined equity issuance through its ATM program.

Key Decisions for Investors

• Investors should evaluate the sustainability of the high NOI growth, particularly the ability of the Trilogy segment to continue optimizing its payer mix towards higher-reimbursement Medicare Advantage plans, as this is a primary driver of the upwardly revised guidance.
• Monitor the execution of the over $300 million acquisition pipeline, which is not included in current guidance and represents a significant source of potential upside to FFO per share.
• Assess the company's capital allocation strategy, noting the effective use of its ATM program to reduce leverage to 3.7x net debt-to-EBITDA and fund accretive growth, while remaining aware of potential per-share dilution from future issuances.
• Consider the company's positioning to benefit from long-term senior housing fundamentals, as management's commentary points to a multi-year tailwind from favorable supply-demand dynamics.